A Journey to Reach the Ovary Using Next-Generation Technologies
Abstract
:1. Introduction
2. Gold Nanoparticles as Next-Generation Delivery Systems
3. MicroRNA Therapy as an Innovative Ovarian Protection Approach
4. Targeting the Ovaries
5. Limitations and Perspectives
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018, 391, 1023–1075. [Google Scholar] [CrossRef]
- Chen, C. Pregnancy After Human Oocyte Cryopreservation. Lancet 1986, 327, 884–886. [Google Scholar] [CrossRef]
- Brown, J.; Modell, E.; Obasaju, M.; Ying, Y.K. Natural cycle in-vitro fertilization with embryo cryopreservation prior to chemotherapy for carcinoma of the breast. Hum. Reprod. 1996, 11, 197–199. [Google Scholar] [CrossRef]
- Demeestere, I.; Simon, P.; Emiliani, S.; Delbaere, A.; Englert, Y. Orthotopic and heterotopic ovarian tissue transplantation. Hum. Reprod. Update 2009, 15, 649–665. [Google Scholar] [CrossRef]
- Demeestere, I.; Simon, P.; Dedeken, L.; Moffa, F.; Tsépélidis, S.; Brachet, C.; Delbaere, A.; Devreker, F.; Ferster, A. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum. Reprod. 2015, 30, 2107–2109. [Google Scholar] [CrossRef]
- Dadashzadeh, A.; Moghassemi, S.; Shavandi, A.; Amorim, C.A. A review on biomaterials for ovarian tissue engineering. Acta Biomater. 2021, 135, 48–63. [Google Scholar] [CrossRef]
- Akahori, T.; Woods, D.C.; Tilly, J.L. Female Fertility Preservation through Stem Cell-based Ovarian Tissue Reconstitution In Vitro and Ovarian Regeneration In Vivo. Clin. Med. Insights Reprod. Health 2019, 13, 1179558119848007. [Google Scholar] [CrossRef]
- Morgan, S.; Anderson, R.; Gourley, C.; Wallace, W.; Spears, N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Updat. 2012, 18, 525–535. [Google Scholar] [CrossRef]
- Roness, H.; Gavish, Z.; Cohen, Y.; Meirow, D. Ovarian follicle burnout: A universal phenomenon? Cell Cycle 2013, 12, 3245–3246. [Google Scholar] [CrossRef]
- Gonfloni, S.; Di Tella, L.; Caldarola, S.; Cannata, S.M.; Klinger, F.G.; Di Bartolomeo, C.; Mattei, M.; Candi, E.; De Felici, M.; Melino, G.; et al. Inhibition of the c-Abl–TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat. Med. 2009, 15, 1179–1185. [Google Scholar] [CrossRef]
- Bellusci, G.; Mattiello, L.; Iannizzotto, V.; Ciccone, S.; Maiani, E.; Villani, V.; Diederich, M.; Gonfloni, S. Kinase-independent inhibition of cyclophosphamide-induced pathways protects the ovarian reserve and prolongs fertility. Cell Death Dis. 2019, 10, 726. [Google Scholar] [CrossRef]
- Li, F.; Turan, V.; Lierman, S.; Cuvelier, C.; De Sutter, P.; Oktay, K. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum. Reprod. 2014, 29, 107–113. [Google Scholar] [CrossRef]
- Meirow, D.; Biederman, H.; Anderson, R.A.; Hamish, W.; Wallace, B. Toxicity of Chemotherapy and Radiation on Female Re-production. Clin. Obstet. Gynecol. 2010, 53, 727–739. [Google Scholar] [CrossRef]
- Grosbois, J.; Devos, M.; Demeestere, I. Implications of Nonphysiological Ovarian Primordial Follicle Activation for Fertility Preservation. Endocr. Rev. 2020, 41, 847–872. [Google Scholar] [CrossRef]
- Kalich-Philosoph, L.; Roness, H.; Carmely, A.; Fishel-Bartal, M.; Ligumsky, H.; Paglin, S.; Wolf, I.; Kanety, H.; Sredni, B.; Meirow, D. Cyclophosphamide Triggers Follicle Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility. Sci. Transl. Med. 2013, 5, 185ra62. [Google Scholar] [CrossRef]
- Tanaka, Y.; Kimura, F.; Zheng, L.; Kaku, S.; Takebayashi, A.; Kasahara, K.; Tsuji, S.; Murakami, T. Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity. Exp. Anim. 2018, 67, 493–500. [Google Scholar] [CrossRef]
- Jang, H.; Na, Y.; Hong, K.; Lee, S.; Moon, S.; Cho, M.; Park, M.; Lee, O.-H.; Chang, E.M.; Lee, D.R.; et al. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27Kip1promoter in primordial follicles. J. Pineal Res. 2017, 63, e12432. [Google Scholar] [CrossRef]
- Lambertini, M.; Horicks, F.; Del Mastro, L.; Partridge, A.H.; Demeestere, I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treat. Rev. 2019, 72, 65–77. [Google Scholar] [CrossRef]
- Lambertini, M.; Boni, L.; Michelotti, A.; Gamucci, T.; Scotto, T.; Gori, S.; Giordano, M.; Garrone, O.; Levaggi, A.; Poggio, F.; et al. Ovarian Suppression with Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A randomized clinical trial. JAMA 2015, 314, 2632–2640. [Google Scholar] [CrossRef]
- Demeestere, I.; Brice, P.; Peccatori, F.; Kentos, A.; Dupuis, J.J.; Zachee, P.; Casasnovas, R.-O.; Van Den Neste, E.; DeChene, J.; De Maertelaer, V.; et al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated with Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J. Clin. Oncol. 2016, 34, 2568–2574. [Google Scholar] [CrossRef]
- Alexandri, C.; Daniel, A.; Bruylants, G.; Demeestere, I. The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: From bench to future clinical application. Hum. Reprod. Updat. 2020, 26, 174–196. [Google Scholar] [CrossRef]
- Travieso, T.; Li, J.; Mahesh, S.; Mello, J.D.F.R.E.; Blasi, M. The use of viral vectors in vaccine development. NPJ Vaccines 2022, 7, 75. [Google Scholar] [CrossRef]
- Mulligan, M.J.; Lyke, K.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K.A.; et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020, 586, 589–593. [Google Scholar] [CrossRef]
- Giljohann, D.A.; Seferos, D.S.; Daniel, W.L.; Massich, M.D.; Patel, P.C.; Mirkin, C.A. Gold Nanoparticles for Biology and Medicine. Angew. Chem. Int. Ed. 2010, 49, 3280–3294. [Google Scholar] [CrossRef]
- Li, S.-D.; Huang, L. Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting. J. Control. Release 2010, 145, 178–181. [Google Scholar] [CrossRef]
- Libutti, S.K.; Paciotti, G.F.; Byrnes, A.A.; Alexander, H.R.; Gannon, W.E.; Walker, M.; Seidel, G.D.; Yuldasheva, N.; Tamarkin, L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin. Cancer Res. 2010, 16, 6139–6149. [Google Scholar] [CrossRef]
- Tatovic, D.; A McAteer, M.; Barry, J.; Barrientos, A.; Terradillos, K.R.; Perera, I.; Kochba, E.; Levin, Y.; Dul, M.; A Coulman, S.; et al. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes. Immunother. Adv. 2022, 2, ltac002. [Google Scholar] [CrossRef]
- Lee, C.-S.; Kim, T.W.; Oh, D.E.; Bae, S.O.; Ryu, J.; Kong, H.; Jeon, H.; Seo, H.K.; Jeon, S.; Kim, T.H. In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment. Cancers 2020, 12, 634. [Google Scholar] [CrossRef]
- Banu, H.; Stanley, B.; Faheem, S.M.; Seenivasan, R.; Premkumar, K.; Vasanthakumar, G. Thermal Chemosensitization of Breast Cancer Cells to Cyclophosphamide Treatment Using Folate Receptor Targeted Gold Nanoparticles. Plasmonics 2014, 9, 1341–1349. [Google Scholar] [CrossRef]
- Xiong, X.; Arvizo, R.R.; Saha, S.; Robertson, D.J.; McMeekin, S.; Bhattacharya, R.; Mukherjee, P. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget 2014, 5, 6453–6465. [Google Scholar] [CrossRef]
- Khoobchandani, M.; Katti, K.K.; Karikachery, A.R.; Thipe, V.C.; Srisrimal, D.; Mohandoss, D.K.D.; Darshakumar, R.D.; Joshi, C.M.; Katti, K.V. New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine—Pre-Clinical and Pilot Human Clinical Investigations. Int. J. Nanomed. 2020, 15, 181–197. [Google Scholar] [CrossRef]
- Kumthekar, P.; Ko, C.H.; Paunesku, T.; Dixit, K.; Sonabend, A.M.; Bloch, O.; Tate, M.; Schwartz, M.; Zuckerman, L.; Lezon, R.; et al. A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. Sci. Transl. Med. 2021, 13, eabb3945. [Google Scholar] [CrossRef]
- Hong, D.S.; Kang, Y.K.; Borad, M.; Sachdev, J.; Ejadi, S.; Lim, H.Y.; Brenner, A.J.; Park, K.; Lee, J.L.; Kim, T.Y.; et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 2020, 122, 1630–1637. [Google Scholar] [CrossRef]
- Goddard, Z.R.; Marín, M.J.; Russell, D.A.; Searcey, M. Active targeting of gold nanoparticles as cancer therapeutics. Chem. Soc. Rev. 2020, 49, 8774–8789. [Google Scholar] [CrossRef]
- Patra, C.R.; Bhattacharya, R.; Wang, E.; Katarya, A.; Lau, J.S.; Dutta, S.; Muders, M.; Wang, S.; Buhrow, S.A.; Safgren, S.L.; et al. Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent. Cancer Res. 2008, 68, 1970–1978. [Google Scholar] [CrossRef]
- Kotcherlakota, R.; Vydiam, K.; Srinivasan, D.J.; Mukherjee, S.; Roy, A.; Kuncha, M.; Rao, T.N.; Sistla, R.; Gopal, V.; Patra, C.R. Restoration of p53 Function in Ovarian Cancer Mediated by Gold Nanoparticle-Based EGFR Targeted Gene Delivery System. ACS Biomater. Sci. Eng. 2019, 5, 3631–3644. [Google Scholar] [CrossRef]
- Kotcherlakota, R.; Srinivasan, D.J.; Mukherjee, S.; Haroon, M.M.; Dar, G.H.; Venkatraman, U.; Patra, C.R.; Gopal, V. Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer. J. Mater. Chem. B 2017, 5, 7082–7098. [Google Scholar] [CrossRef]
- Behzadi, S.; Serpooshan, V.; Tao, W.; Hamaly, M.A.; Alkawareek, M.Y.; Dreaden, E.C.; Brown, D.; Alkilany, A.M.; Farokhzad, O.C.; Mahmoudi, M. Cellular uptake of nanoparticles: Journey inside the cell. Chem. Soc. Rev. 2017, 46, 4218–4244. [Google Scholar] [CrossRef]
- Ding, Y.; Jiang, Z.; Saha, K.; Kim, C.S.; Kim, S.T.; Landis, R.F.; Rotello, V.M. Gold Nanoparticles for Nucleic Acid Delivery. Mol. Ther. 2014, 22, 1075–1083. [Google Scholar] [CrossRef]
- Lee, K.; Conboy, M.; Park, H.M.; Jiang, F.; Kim, H.J.; Dewitt, M.A.; Mackley, V.A.; Chang, K.; Rao, A.; Skinner, C.; et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 2017, 1, 889–901. [Google Scholar] [CrossRef]
- Fedoryshin, L.L.; Tavares, A.J.; Petryayeva, E.; Doughan, S.; Krull, U.J. Near-Infrared-Triggered Anticancer Drug Release from Upconverting Nanoparticles. ACS Appl. Mater. Interfaces 2014, 6, 13600–13606. [Google Scholar] [CrossRef]
- Stern, J.M.; Solomonov, V.V.K.; Sazykina, E.; Schwartz, J.A.; Gad, S.C.; Goodrich, G.P. Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. Int. J. Toxicol. 2016, 35, 38–46. [Google Scholar] [CrossRef]
- Rastinehad, A.R.; Anastos, H.; Wajswol, E.; Winoker, J.S.; Sfakianos, J.P.; Doppalapudi, S.K.; Carrick, M.R.; Knauer, C.J.; Taouli, B.; Lewis, S.C.; et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc. Natl. Acad. Sci. USA 2019, 116, 18590–18596. [Google Scholar] [CrossRef]
- Kharlamov, A.N.; Tyurnina, A.E.; Veselova, V.S.; Kovtun, O.P.; Shur, V.Y.; Gabinsky, J.L. Silica–gold nanoparticles for atheroprotective management of plaques: Results of the NANOM-FIM trial. Nanoscale 2015, 7, 8003–8015. [Google Scholar] [CrossRef]
- Bucharskaya, A.B.; Khlebtsov, N.G.; Khlebtsov, B.N.; Maslyakova, G.N.; Navolokin, N.A.; Genin, V.D.; Genina, E.A.; Tuchin, V.V. Photothermal and Photodynamic Therapy of Tumors with Plasmonic Nanoparticles: Challenges and Prospects. Materials 2022, 15, 1606. [Google Scholar] [CrossRef]
- Saha, K.; Agasti, S.S.; Kim, C.; Li, X.; Rotello, V.M. Gold Nanoparticles in Chemical and Biological Sensing. Chem. Rev. 2012, 112, 2739–2779. [Google Scholar] [CrossRef]
- Vucic, S.; Kiernan, M.C.; Menon, P.; Huynh, W.; Rynders, A.; Ho, K.S.; Glanzman, R.; Hotchkin, M.T. Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open 2021, 11, e041479. [Google Scholar] [CrossRef]
- Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350–355. [Google Scholar] [CrossRef]
- Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [Google Scholar] [CrossRef]
- Feinbaum, R.; Ambros, V.; Lee, R.; The, C. Elegans Heterochronic Gene Lin-4 Encodes Small RNAs with Antisense Comple-mentarity to Lin-14. Cell 1993, 116, 843–854. [Google Scholar]
- Friedman, R.C.; Farh, K.K.-H.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92–105. [Google Scholar] [CrossRef]
- Alles, J.; Fehlmann, T.; Fischer, U.; Backes, C.; Galata, V.; Minet, M.; Hart, M.; Abu-Halima, M.; Grässer, F.A.; Lenhof, H.-P.; et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019, 47, 3353–3364. [Google Scholar] [CrossRef]
- Lindow, M.; Kauppinen, S. Discovering the first microRNA-targeted drug. J. Cell Biol. 2012, 199, 407–412. [Google Scholar] [CrossRef]
- van der Ree, M.H.; van der Meer, A.J.; van Nuenen, A.C.; de Bruijne, J.; Ottosen, S.; Janssen, H.L.; Kootstra, N.A.; Reesink, H.W. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment. Pharmacol. Ther. 2015, 43, 102–113. [Google Scholar] [CrossRef]
- Regulus Therapeutics Inc. Regulus Announces Pipeline Updates and Advancements. Available online: https://www.prnewswire.com/news-releases/regulus-announces-pipeline-updates-and-advancements-300472142.html (accessed on 14 August 2023).
- Gallant-Behm, C.L.; Piper, J.; Lynch, J.M.; Seto, A.G.; Hong, S.J.; Mustoe, T.A.; Maari, C.; Pestano, L.A.; Dalby, C.M.; Jackson, A.L.; et al. A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J. Investig. Dermatol. 2019, 139, 1073–1081. [Google Scholar] [CrossRef]
- van Zandwijk, N.; Pavlakis, N.; Kao, S.C.; Linton, A.; Boyer, M.J.; Clarke, S.; Huynh, Y.; Chrzanowska, A.; Fulham, M.J.; Bailey, D.L.; et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017, 18, 1386–1396. [Google Scholar] [CrossRef]
- Reid, G.; Pel, M.E.; Kirschner, M.B.; Cheng, Y.Y.; Mugridge, N.; Weiss, J.; Williams, M.; Wright, C.; Edelman, J.J.B.; Vallely, M.P.; et al. Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 2013, 24, 3128–3135. [Google Scholar] [CrossRef]
- Kristen, A.V.; Ajroud-Driss, S.; Conceição, I.; Gorevic, P.; Kyriakides, T.; Obici, L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manag. 2019, 9, 5–23. [Google Scholar] [CrossRef]
- Riolo, G.; Cantara, S.; Marzocchi, C.; Ricci, C. miRNA Targets: From Prediction Tools to Experimental Validation. Methods Protoc. 2021, 4, 1. [Google Scholar] [CrossRef]
- Meng, F.; Henson, R.; Lang, M.; Wehbe, H.; Maheshwari, S.; Mendell, J.T.; Jiang, J.; Schmittgen, T.D.; Patel, T. Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell Lines. Gastroenterology 2006, 130, 2113–2129. [Google Scholar] [CrossRef]
- Hummel, R.; Wang, T.; Watson, D.I.; Michael, M.Z.; Van der Hoek, M.; Haier, J.; Hussey, D.J. Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol. Rep. 2011, 26, 1011–1017. [Google Scholar] [CrossRef]
- Lindholm, E.M.; Aure, M.R.; Haugen, M.H.; Sahlberg, K.K.; Kristensen, V.N.; Nebdal, D.; Børresen-Dale, A.; Lingjærde, O.C.; Engebraaten, O. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Mol. Oncol. 2019, 13, 2278–2296. [Google Scholar] [CrossRef]
- Ma, J.; Dong, C.; Ji, C. MicroRNA and drug resistance. Cancer Gene Ther. 2010, 17, 523–531. [Google Scholar] [CrossRef]
- Blower, P.E.; Chung, J.-H.; Verducci, J.S.; Lin, S.; Park, J.-K.; Dai, Z.; Liu, C.-G.; Schmittgen, T.D.; Reinhold, W.C.; Croce, C.M.; et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 2008, 7, 1–9. [Google Scholar] [CrossRef]
- Zhu, H.; Wu, H.; Liu, X.; Evans, B.R.; Medina, D.J.; Liu, C.-G.; Yang, J.-M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 2008, 76, 582–588. [Google Scholar] [CrossRef]
- Serguienko, A.; Grad, I.; Wennerstrøm, A.B.; Meza-Zepeda, L.A.; Thiede, B.; Stratford, E.W.; Myklebost, O.; Munthe, E. Metabolic reprogramming of metastatic breast cancer and melanoma by let-7amicroRNA. Oncotarget 2015, 6, 2451–2465. [Google Scholar] [CrossRef]
- Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; et al. let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell 2007, 131, 1109–1123. [Google Scholar] [CrossRef]
- Yin, P.T.; Pongkulapa, T.; Cho, H.-Y.; Han, J.; Pasquale, N.J.; Rabie, H.; Kim, J.-H.; Choi, J.-W.; Lee, K.-B. Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core–Shell Nanoparticles. ACS Appl. Mater. Interfaces 2018, 10, 26954–26963. [Google Scholar] [CrossRef]
- De Guire, V.; Robitaille, R.; Tétreault, N.; Guérin, R.; Ménard, C.; Bambace, N.; Sapieha, P. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: Promises and challenges. Clin. Biochem. 2013, 46, 846–860. [Google Scholar] [CrossRef]
- Meiri, E.; Mueller, W.C.; Rosenwald, S.; Zepeniuk, M.; Klinke, E.; Edmonston, T.B.; Werner, M.; Lass, U.; Barshack, I.; Feinmesser, M.; et al. A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue Origin. Oncologist 2012, 17, 801–812. [Google Scholar] [CrossRef]
- Xiao, G.-Y.; Cheng, C.-C.; Chiang, Y.-S.; Cheng, W.T.-K.; Liu, I.-H.; Wu, S.-C. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci. Rep. 2016, 6, 23120. [Google Scholar] [CrossRef]
- Alexandri, C.; Stratopoulou, C.-A.; Demeestere, I. Answer to Controversy: miR-10a Replacement Approaches Do Not Offer Protection against Chemotherapy-Induced Gonadotoxicity in Mouse Model. Int. J. Mol. Sci. 2019, 20, 4958. [Google Scholar] [CrossRef]
- Alexandri, C.; Stamatopoulos, B.; Rothé, F.; Bareche, Y.; Devos, M.; Demeestere, I. MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries. Sci. Rep. 2019, 9, 9636. [Google Scholar] [CrossRef]
- Alexandri, C.; Van Den Steen, G.; Demeestere, I. Let-7a mimic transfection reduces chemotherapy-induced damage in a mouse ovarian transplantation model. Sci. Rep. 2022, 12, 10863. [Google Scholar] [CrossRef]
- Fu, X.; He, Y.; Wang, X.; Peng, D.; Chen, X.; Li, X.; Wang, Q. Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to inhibit granulosa cell apoptosis. Stem Cell Res. Ther. 2017, 8, 187. [Google Scholar] [CrossRef]
- Thabet, E.; Yusuf, A.; Abdelmonsif, D.A.; Nabil, I.; Mourad, G.; A Mehanna, R. Extracellular vesicles miRNA-21: A potential therapeutic tool in premature ovarian dysfunction. Mol. Hum. Reprod. 2020, 26, 906–919. [Google Scholar] [CrossRef]
- Yang, M.; Lin, L.; Sha, C.; Li, T.; Zhao, D.; Wei, H.; Chen, Q.; Liu, Y.; Chen, X.; Xu, W.; et al. Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. Lab. Investig. 2020, 100, 342–352. [Google Scholar] [CrossRef]
- Cao, R.-C.; Lv, Y.; Lu, G.; Liu, H.-B.; Wang, W.; Tan, C.; Su, X.-W.; Xiong, Z.; Ma, J.-L.; Chan, W.-Y. Extracellular vesicles from iPSC-MSCs alleviate chemotherapy-induced mouse ovarian damage via the ILK-PI3K/AKT pathway. Zool. Res. 2023, 44, 620–635. [Google Scholar] [CrossRef]
- Liu, M.; Xiao, B.; Zhu, Y.; Chen, M.; Huang, J.; Guo, H.; Wang, F. MicroRNA-144-3p protects against chemotherapy-induced apoptosis of ovarian granulosa cells and activation of primordial follicles by targeting MAP3K9. Eur. J. Med. Res. 2023, 28, 264. [Google Scholar] [CrossRef]
- Domínguez-Ríos, R.; Sánchez-Ramírez, D.R.; Ruiz-Saray, K.; Oceguera-Basurto, P.E.; Almada, M.; Juárez, J.; Zepeda-Moreno, A.; del Toro-Arreola, A.; Topete, A.; Daneri-Navarro, A. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf. B Biointerfaces 2019, 178, 199–207. [Google Scholar] [CrossRef]
- Kumar, D.; Moghiseh, M.; Chitcholtan, K.; Mutreja, I.; Lowe, C.; Kaushik, A.; Butler, A.; Sykes, P.; Anderson, N.; Raja, A. LHRH conjugated gold nanoparticles assisted efficient ovarian cancer targeting evaluated via spectral photon-counting CT imaging: A proof-of-concept research. J. Mater. Chem. B 2023, 11, 1916–1928. [Google Scholar] [CrossRef]
- Khayrani, A.C.; Mahmud, H.; Oo, A.K.K.; Zahra, M.H.; Oze, M.J.; Du, J.; Alam, M.J.; Afify, S.M.; Abu Quora, H.A.; Shigehiro, T.; et al. Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. Int. J. Mol. Sci. 2019, 20, 1042. [Google Scholar] [CrossRef]
- Skubitz, A.P.N.; Taras, E.P.; Boylan, K.L.M.; Waldron, N.N.; Oh, S.; Panoskaltsis-Mortari, A.; Vallera, D.A. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol. Oncol. 2013, 130, 579–587. [Google Scholar] [CrossRef]
- Oktem, O.; Oktay, K. The Ovary: Anatomy and Function throughout Human Life. Ann. N. Y. Acad. Sci. 2008, 1127, 1–9. [Google Scholar] [CrossRef]
- The Human Protein Atlas. Available online: https://www.proteinatlas.org/ (accessed on 18 August 2023).
- Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Tissue-Based Map of the Human Proteome. Science 2015, 347, 1260419. [Google Scholar] [CrossRef]
- Zhang, Y.; Yan, Z.; Qin, Q.; Nisenblat, V.; Chang, H.-M.; Yu, Y.; Wang, T.; Lu, C.; Yang, M.; Yang, S.; et al. Transcriptome Landscape of Human Folliculogenesis Reveals Oocyte and Granulosa Cell Interactions. Mol. Cell 2018, 72, 1021–1034.e4. [Google Scholar] [CrossRef]
- Chen, Y.-Y.; Russo, D.D.; Drake, R.S.; Duncan, F.E.; Shalek, A.K.; Goods, B.A.; Woodruff, T.K. Single-cell transcriptomics of staged oocytes and somatic cells reveal novel regulators of follicle activation. Reproduction 2022, 164, 55–70. [Google Scholar] [CrossRef]
- Kocabas, A.M.; Crosby, J.; Ross, P.J.; Otu, H.H.; Beyhan, Z.; Can, H.; Tam, W.-L.; Rosa, G.J.M.; Halgren, R.G.; Lim, B.; et al. The transcriptome of human oocytes. Proc. Natl. Acad. Sci. USA 2006, 103, 14027–14032. [Google Scholar] [CrossRef]
- Sani, A.; Cao, C.; Cui, D. Toxicity of gold nanoparticles (AuNPs): A review. Biochem. Biophys. Rep. 2021, 26, 100991. [Google Scholar] [CrossRef]
- Poley, M.; Mora-Raimundo, P.; Shammai, Y.; Kaduri, M.; Koren, L.; Adir, O.; Shklover, J.; Shainsky-Roitman, J.; Ramishetti, S.; Man, F.; et al. Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Cancer Treatment and Fertility. ACS Nano 2022, 16, 5246–5257. [Google Scholar] [CrossRef]
- Alkilany, A.M.; Murphy, C.J. Toxicity and cellular uptake of gold nanoparticles: What we have learned so far? J. Nanoparticle Res. 2010, 12, 2313–2333. [Google Scholar] [CrossRef]
- Balfourier, A.; Luciani, N.; Wang, G.; Lelong, G.; Ersen, O.; Khelfa, A.; Alloyeau, D.; Gazeau, F.; Carn, F. Unexpected intracellular biodegradation and recrystallization of gold nanoparticles. Proc. Natl. Acad. Sci. USA 2020, 117, 103–113. [Google Scholar] [CrossRef]
- Balfourier, A.; Kolosnjaj-Tabi, J.; Luciani, N.; Carn, F.; Gazeau, F.; Murphy, C.J. Gold-based therapy: From past to present. Proc. Natl. Acad. Sci. USA 2020, 117, 22639–22648. [Google Scholar] [CrossRef]
- Krusius, F.E.; Markkanen, A.; Peltola, P. Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis. Ann. Rheum. Dis. 1970, 29, 232–235. [Google Scholar] [CrossRef]
- Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory Responses and Inflammation-Associated Diseases in Organs. Oncotarget 2018, 9, 7204–7218. [Google Scholar] [CrossRef]
Name | Molecule | AuNPs | Administration Route | Treatment | Clinical Phase |
---|---|---|---|---|---|
CYT-6091 | rhTNF | 27 nm PEGylated | Isolation perfusion at the extremity | Various solid tumor | Phase I (NCT00356980) 2006–2009 |
C19-A3 | Proinsulin peptide | 5 nm | Microneedle injection | Type I diabetes | Phase I (NCT02837094) 2016- |
Nano Swarna Bhasma | Combination of phytochemicals | 35 nm | Oral capsule | Breast cancer | Phase 0 DNA_SPN_B001_17 AYUSH |
NU-0129 | RNAi for Bcl2L12 | 13 nm Thiolated PEG | Intravenous injection | Gliobastoma | Phase 0 (NCT03020017) 2017–2020 |
DengueTcP (EMX-001) | Synthetic T cell-selective multivalent with dengue virus peptide antigens vaccine | 5 nm | Intradermal injection | Dengue fever | Phase I (NCT04935801) 2021- |
Corona TcP | Betacoronavirus T cell-priming immune vaccine | 5 nm | Intradermal injection | SARS-CoV-2 | Phase I (NCT05113862) 2022- |
Name | Molecule | Delivery System | Treatment | Target | Clinical Phase |
---|---|---|---|---|---|
Miravirsen (RG101) | Anti-miR-122 | LNA-antisense | Chronic hepatitis C | Liver | Phase II (NCT01727934) 2012–2014 Unknown |
MRX34 | miR-34 mimic | LNPs | Advanced solid tumors | Tumor | Phase I (NCT02862145) 2016–2017 Withdrawn |
MesomiR-1 | miR-16 mimic | EnGeneIC Dream Vectors | Malignant pleural mesothelioma | Tumor expressing EGFR | Phase I (NCT02369198) 2014–2017 Completed |
Lademirsen (RG-012) | Anti-miR-21 | Oligonucleotides modification | Alport Syndrome | Kidney | Phase II Suspended |
Cobomarsen (MRG-106) | Anti-miR-155 | LNA-antisense | Mycosis fungoides | Skin | Phase II (NCT03713320) 2019–2020 Terminated 1 |
TLV-associated adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia | Lymphatic system | Phase I (NCT02580552) 2016–2020 Completed | |||
Remlarsen (MRG-201) | miR-29 mimic | LNA-mimic | Fibrotic diseases | Phase II (NCT03601052) 2018–2020 Completed | |
Obefazimob (ABX464) | miR-124 mimic | Capsule (oral administration) | Active Rheumatoid Arthritis | Immune system | Phase II (NCT05177835) 2021- Recruiting |
Ulcerative Colitis | Phase III (NCT05507203) 2022- Recruiting |
Name | Abbreviation | Proposed Cell Specificity | Model | Ovarian RNA Expression 1 | Location |
---|---|---|---|---|---|
Alanine and Arginine-rich Domain Containing Protein | AARD | GCs | Human | N/M | Intracellular |
Aldehyde Dehydrogenase 1 Family Member A2 | ALDH1A2 | GCs | Human | Endometrial stromal cells | Intracellular |
Anti-Müllerian Hormone | AMH | GCs | Mouse and human | GCs | Secreted |
Anti-Müllerian Hormone Receptor Type 2 | AMHR2 | GCs | Human | GCs | Membrane, Intracellular |
Bone Morphogenetic Protein 15 | BMP15 | Oocytes | Human | N/M | Secreted |
Bone Morphogenetic Protein Receptor Type 2 | BMPR2 | Oocytes | Human | N/M | Membrane |
Cytochrome P450 Family 11 Subfamily A Member 1 | CYP11A1 | GCs | Mouse and human | N/M | Intracellular |
Cytochrome P450 Family 19 Subfamily A Member 1 | CYP19A1 | GCs | Human | N/M | Membrane, Intracellular |
Deleted in Azoospermia Like | DAZL | Oocytes | Mouse and human | Oocytes | Intracellular |
DEAD-Box Helicase 4 | DDX4 | Oocytes | Mouse and human | Oocytes | Intracellular |
Developmental Pluripotency Associated 3 | DPPA3 | Oocytes | Human | Oocytes | Intracellular |
Folliculogenesis Specific Bhlh Transcription Factor | FIGLA | Oocytes | Human | Oocytes | Intracellular |
Forkhead Box L2 | FOXL2 | GCs | Human | GCs, Ovarian stromal cells, Endometrial stromal cells | Intracellular |
Follicle Stimulating Hormone Receptor | FSHR | GCs | Human | GCs | Membrane, Intracellular |
Follistatin | FST | GCs | Human | GCs | Secreted, Intracellular |
Glycine Amidinotransferase | GATM | GCs | Human | GCs | Intracellular |
Growth Differentiation Factor 9 | GDF9 | Oocytes | Human | Oocytes | Secreted, Intracellular |
G Protein Subunit Gamma 13 | GNG13 | GCs | Human | N/M | Intracellular |
H1.8 Linker Histone | H1FOO | Oocytes GCs | Human Mouse | Oocytes | Intracellular |
3-Hydroxy-3-Methylglutaryl- CoA Synthase 2 | HMGCS2 | GCs | Human | N/M | Intracellular |
Inhibin Subunit Alpha | INHA | GCs | Mouse and human | GCs Ovarian stromal cells | Secreted |
Inhibin Subunit Beta A | INHBA | GCs | Mouse and human | N/M | Secreted |
KIT Ligand | KITL | GCs | Human | N/M | Membrane, Intracellular |
Keratin 8 | KRT8 | GCs | Human | N/M | Intracellular |
Keratin 19 | KRT19 | GCs | Human | N/M | Intracellular |
Luteinizing Hormone/ Choriogonadotropin Receptor | LHCGR | GCs | Human | Ovarian stromal cells | Membrane, Intracellular |
LIM Homeobox 8 | LHX8 | Oocytes | Mouse and human | Oocytes | Intracellular |
NOBOX Oogenesis Homeobox | NOBOX | Oocytes | Human | Oocytes | Intracellular |
Nucleophosmin/ Nucleoplasmin 2 | NPM2 | Oocytes | Human | Oocytes | Intracellular |
Oocyte-Specific Gene | OOG1 | Oocytes | Human | Oocytes | Intracellular |
POU Class 5 Homeobox 1 | POU5F1 | Oocytes | Human | N/M | Intracellular |
RNA Polymerase I Subunit A | RPO1 | GCs | Human | N/M | Intracellular |
Spermatogenesis and Oogenesis Specific Basic Helix-Loop-Helix 1 | SOHLH1 | Oocytes | Human | Oocytes | Intracellular |
SRY-Box Transcription Factor 30 | SOX30 | Oocytes | Mouse and human | N/M | Intracellular |
Steroidogenic Acute Regulatory Protein | STAR | GCs | Mouse and human | Ovarian stromal cells | Intracellular |
SUB1 Regulator of Transcription | SUB1 | Oocytes | Human | N/M | Intracellular |
Synaptonemal Complex Protein 3 | SYCP3 | Oocytes | Mouse and human | Oocytes | Intracellular |
TATA-Box Binding Protein-Associated Factor 7 Like | TAF7L | Oocytes | Human | N/M | Intracellular |
Transforming growth factor beta receptor 1 | TGFBR1 | Oocytes | Human | N/M | |
Uroplakin 3B | UPK3B | GCs | Human | N/M | Membrane, Intracellular |
Y-Box Binding Protein 2 | YBX2 | Oocytes | Mouse and human | N/M | Intracellular |
Zygote Arrest 1 | ZAR1 | Oocytes | Mouse and human | Oocytes | Intracellular |
Zona Pellucida Glycoprotein 2 | ZP-2 | Oocytes | Mouse and human | N/M | Secreted, Membrane |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nguyen, T.T.A.; Demeestere, I. A Journey to Reach the Ovary Using Next-Generation Technologies. Int. J. Mol. Sci. 2023, 24, 16593. https://doi.org/10.3390/ijms242316593
Nguyen TTA, Demeestere I. A Journey to Reach the Ovary Using Next-Generation Technologies. International Journal of Molecular Sciences. 2023; 24(23):16593. https://doi.org/10.3390/ijms242316593
Chicago/Turabian StyleNguyen, Thuy Truong An, and Isabelle Demeestere. 2023. "A Journey to Reach the Ovary Using Next-Generation Technologies" International Journal of Molecular Sciences 24, no. 23: 16593. https://doi.org/10.3390/ijms242316593